kool

Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 1

check it out "KOOL", the time to buy is now.

Bridgford Foods: A Peter Lynch Ten-Bagger?

I bet Thermogenesis (KOOL) will be a 5 bagger in 12 months.

What Will Happen 5 Years from Now?

I bet Thermogenesis (KOOL) will be a 5 bagger in 12 months.

5 Ultra Low Priced Summertime Stock Suggestions

I bet Thermogenesis (KOOL) will be a 5 bagger in 12 months.

Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 2

The best cord blood banks of the world like CBR and NECBB...etc. have been spending $$$ up-grading their processing and cryo-preserving devices to Thermogenesis (KOOL)'s AXP and BioArchive. KOOL is at the begining of industry-wide upgrading cycle.

Those cheaper ones are using the outdated equipments handing the precious cord blood. The AXP extracts 98+% of all stem cells out while outdated ones get at most 60-70%

By the way KOOL is about to become profitable... as soon as this current quarter (July-sep., 2009).

Book Review - Reading Minds and Markets

I bet sometimes technical of a stock is being shaped up by the fundmental of that company.... i believe when a stock's 50 day MA just crossed it's 200 day MA on the way up 1st time in 2 1/2 years says a lot about the improvement of its fundmental healthiness.

Look at this chart of Thermogenesis (KOOL).
finance.yahoo.com/echa...;range=1y;indicator=sm...

Buffett's Lessons: More Appropriate than Ever

very solid way of thinking process and it's totally a must in choosing a company to invest.

i recently picked a company, although it's in a turn-around stage but it's solid and has a huge space to grow in regenerative medicine. it has a new CEO who is proven to be a turn-around expert with very low key, doing more than he said, the company is Thermogenesis (KOOL). Check it out, they can either break-even or make a profit as soon as this current quarter.

How's the Economy Doing? A Look Under the Hood in August

Everything happened for a good reason, in this case.... the technical is influenced by the fundmental, in my humble opinion.

For its 20 some years' existence, Thermogenesis (KOOL) initially in blood rapid freezing/thawing to the most recent 3 years in cord blood processing, storage equipments and stem cell process clinical devices.... Now is the closest time to become sustainable operational profitable.

The technical shows that, the 50 ma crossed 200 ma just recently....

Lots changes has been made since outage of Osgood...

1. scraped the equine lab. - a money drainer and distraction of business focus.

2. reorginized the organization and trimed the cost significantly.

3. prioritized the R&D items and spending.

4. focused on product quality and customer services.

5.introduced new products MXP and Res-Q.

6. rebuilding sales organization.

7. hired the a proven new CEO.

Based on current cost structure, our quarterly operation cost is at about $5.2-$5.6 millions, we reached this revenue in fy 2008 already.

With the expanded business in both cord blood and bone marrow stem cell processing, our sustainable profitability is just right at the corner.

Betting on Obama's Healthcare Proposals

don't bet, invest in good solid growing company.... This one is Thermogenesis (KOOL).

Everything happened for a good reason, in this case.... the technical is influenced by the fundmental, in my humble opinion.

For its 20 some years' existence, initially in blood rapid freezing/thawing to the most recent 3 years in cord blood processing, storage equipments and stem cell process clinical devices.... Now is the closest time to become sustainable operational profitable.

The technical shows that, the 50 ma crossed 200 ma just recently....

Lots changes has been made since outage of Osgood...

1. scraped the equine lab. - a money drainer and distraction of business focus.

2. reorginized the organization and trimed the cost significantly.

3. prioritized the R&D items and spending.

4. focused on product quality and customer services.

5.introduced new products MXP and Res-Q.

6. rebuilding sales organization.

7. hired the a proven new CEO.

Based on current cost structure, our quarterly operation cost is at about $5.2-$5.6 millions, we reached this revenue in fy 2008 already.

With the expanded business in both cord blood and bone marrow stem cell processing, our sustainable profitability is just right at the corner.

Adult Stem Cell Drugs and Therapies Are the Next Big Market

Thermogenesis (KOOL) is about to become profitable from operation, 1st stem cell related... As soon as this current quarter(July-Sep., 2009).

Ample cash, no debt.

Finding the 'Mythical' 100-Bagger

don't know if it will be a 100 bagger but 90% sure it'll be a 10 bagger soon. Thermogenesis (KOOL).

check it out.

Capstone Therapeutics: Q2 Update

my favorite regenerative medicine play is still the leader of adult stem processing and storage device maker Thermogenesis (KOOL), it'll be the 1st to become profitable this current quarter.

due to hitting some rough patches the past 2 years, the market is at "show me the money mode" toward this company.

the new CEO has been very low key doing all the fixes he needed to turn this issue around big time. it's still dirt cheap, a 5-10 bagger in 12 months.

don't just listen to me, check it out yourself.

Onyx Pharmaceuticals: Good Reasons for Raising Capital, Investors Overly Concerned

my favorite regenerative medicine play is still the leader of adult stem processing and storage device maker Thermogenesis (KOOL), it'll be the 1st to become profitable this current quarter.

due to hitting some rough patches the past 2 years, the market is at "show me the money mode" toward this company.

the new CEO has been very low key doing all the fixes he needed to turn this issue around big time. it's still dirt cheap, a 5-10 bagger in 12 months.

don't just listen to me, check it out yourself.

10 Biotechs in Stem Cells that Could Profit Under the Democrats

best investment in this stage of stem cell research and therapies is investing in the leader of stem cell processing and storage devices maker Thermogenesis (KOOL).

plenty of cash, no debt and very likely to become profitable from this quarter on (june-august, 2009).

check it out.

Reversal of Stem Cell Research Ban: 13 Stocks to Benefit

KOOL is the one to own now, a 5-10 bagger in a year or so, in my humble opinion.